0.00Open11.00Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover0.00%IV5.04%PremiumDec 6, 2024Expiry Date8.55Intrinsic Value100Multiplier-4DDays to Expiry2.45Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.41Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Viking Therapeutics Stock Discussion
loading...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
🚀🚀🚀🚀 now all engines firing
No comment yet